Biomarin Pharmaceutical Inc banner

Biomarin Pharmaceutical Inc
NASDAQ:BMRN

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Watchlist
Price: 60.32 USD -0.94% Market Closed
Market Cap: $11.6B

Relative Value

The Relative Value of one BMRN stock under the Base Case scenario is hidden USD. Compared to the current market price of 60.32 USD, Biomarin Pharmaceutical Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BMRN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

BMRN Competitors Multiples
Biomarin Pharmaceutical Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
11.7B USD 3.6 33.1 11.1 12.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
402.5B USD 6.6 96.2 15.8 21.9
US
Amgen Inc
NASDAQ:AMGN
203.5B USD 5.5 26.4 15.1 15.1
US
Gilead Sciences Inc
NASDAQ:GILD
181.2B USD 6.2 21.3 13.3 16.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
125.1B USD 10.4 31.6 23.9 25
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.9B USD 5.7 18.2 13.6 15.5
AU
CSL Ltd
ASX:CSL
68.7B AUD 3.2 34.9 11.5 14.5
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
39.2B EUR 11 35.2 38.3 39.1
P/S Multiple
Revenue Growth P/S to Growth
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Average P/S: 3 063 003.3
3.6
13%
0.3
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.5
3%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.2
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.4
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
11
27%
0.4
P/E Multiple
Earnings Growth PEG
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Average P/E: 37.1
33.1
58%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
96.2
97%
1
US
Amgen Inc
NASDAQ:AMGN
26.4
20%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
21.3
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.6
16%
2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
AU
CSL Ltd
ASX:CSL
34.9
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
35.2
32%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Average EV/EBITDA: 17.8
11.1
14%
0.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.8
12%
1.3
US
Amgen Inc
NASDAQ:AMGN
15.1
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
9%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
18%
0.8
AU
CSL Ltd
ASX:CSL
11.5
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
38.3
50%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Average EV/EBIT: 19.9
12.2
13%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.9
24%
0.9
US
Amgen Inc
NASDAQ:AMGN
15.1
3%
5
US
Gilead Sciences Inc
NASDAQ:GILD
16.4
13%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.5
23%
0.7
AU
CSL Ltd
ASX:CSL
14.5
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
39.1
56%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett